Cutaneous toxicities of antiretroviral therapy for HIV Part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors

Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Journal of the American Academy of Dermatology (Impact Factor: 4.45). 10/2010; 63(4):549-61; quiz 561-2. DOI: 10.1016/j.jaad.2010.01.061
Source: PubMed


Antiretroviral medications for the treatment of HIV are common drugs with diverse and frequent skin manifestations. Multiple new cutaneous effects have been recognized in the past decade. Dermatologists play an important role in accurately diagnosing and managing the cutaneous toxicities of these medications, thereby ensuring that a patient has as many therapeutic options as possible for life-long viral suppression. Part I of this two-part series on the cutaneous adverse effects of antiretroviral medications will discuss HIV-associated lipodystrophy syndrome, which can be seen as a result of many antiretroviral medications for HIV, and the specific cutaneous effects of the nucleoside reverse transcriptase inhibitors and protease inhibitors.

5 Reads
Show more